Articles tagged with Pancreatic Tumors
Scientists at the University of Utah Health have discovered an enzyme called DGK iota that appears to reduce the incidence of Ras-induced tumors in mice. The researchers found that mice with a deleted DGK iota gene developed fewer tumors, while those with an intact gene and activated Ras exhibited significantly more tumors.
Breast cancer tumors hijack normal wound-healing processes by exploiting stromal cells' production of SDF-1, which recruits endothelial precursor cells for tumor growth. This process enables tumors to access nutrients and grow unchecked.
A recent study published in Annals of Internal Medicine found that high-quality CT scans can accurately determine which pancreatic cancers are treatable, rendering endoscopic ultrasound unnecessary. The study also revealed that CT scans were more accurate in detecting new cancers and determining the stage of the disease.
Cohen's team found that fibroblast activation protein (FAP) and focal adhesion kinase (FAK) are overexpressed in over 90% of pancreatic adenocarcinomas, suggesting they may contribute to poor outcomes. However, selective inhibition of these proteins shows promise in preclinical models.
The study found that the c-Myc protein has a key cancer-preventing mechanism, causing cell death, but also triggers the growth of invasive tumors when another oncoprotein is activated. Suppressing this mechanism can lead to rapid tumor regression and collapse of blood vessels.
Researchers have shown that four drugs, known as angiogenesis inhibitors, can effectively treat spontaneous tumors at distinct stages of progression in mice. The study provides evidence for the potential of these drugs to act against tumors in a mouse model that more closely resembles human tumor development.
Researchers found that tumors with a specific BRCA2 mutation are more sensitive to radiation and certain chemotherapy drugs. This suggests genetic screening could be used to tailor treatment for patients with this mutation, potentially improving outcomes.
Researchers at Ohio State University have developed a technique to help surgeons determine the extent of tumor spread in pancreatic cancer patients. This method uses an antibody labeled with radioactivity to detect cancer cells, potentially improving treatment outcomes and reducing harm from extensive surgery.